Do analysts prefer WEED or MJN?

Canopy Growth presently has a consensus price target of C$1.88, suggesting a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts clearly believe Canopy Growth is more favorable than Cronos Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, WEED or MJN?

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 1.98 -C$1.05B -C$0.67 N/A Cronos Group N/A N/A N/A N/A N/A

Does the media prefer WEED or MJN?

In the previous week, Canopy Growth had 1 more articles in the media than Cronos Group. MarketBeat recorded 2 mentions for Canopy Growth and 1 mentions for Cronos Group. Canopy Growth's average media sentiment score of 0.78 beat Cronos Group's score of 0.67 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CARA or WEED?

Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher earnings and valuation, CARA or WEED?

Cara Operations has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Canopy Growth C$293.63M 1.98 -C$1.05B -C$0.67 N/A

Which has preferable valuation & earnings, CRON or WEED?

Cronos Group has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$179.09M 8.80 -C$32.78M C$0.19 22.53 Canopy Growth C$293.63M 1.98 -C$1.05B -C$0.67 N/A

Does the media favor CRON or WEED?

In the previous week, Cronos Group and Cronos Group both had 2 articles in the media. Canopy Growth's average media sentiment score of 0.78 beat Cronos Group's score of 0.47 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DHT.UN or WEED?

In the previous week, DRI Healthcare Trust had 3 more articles in the media than Canopy Growth. MarketBeat recorded 5 mentions for DRI Healthcare Trust and 2 mentions for Canopy Growth. DRI Healthcare Trust's average media sentiment score of 1.12 beat Canopy Growth's score of 0.78 indicating that DRI Healthcare Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DRI Healthcare Trust 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate WEED or THCX?

Canopy Growth presently has a consensus target price of C$1.88, indicating a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher possible upside, research analysts plainly believe Canopy Growth is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, WEED or THCX?

Hydropothecary has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 1.98 -C$1.05B -C$0.67 N/A Hydropothecary N/A N/A N/A N/A N/A

Canopy Growth (WEED) Competitors

C$1.38 -0.03 (-2.13%)

As of 12:32 PM Eastern

Compare

WEED vs. MJN, CARA, CRON, DHT.UN, and THCX

Should you buy Canopy Growth stock or one of its competitors? Canopy Growth's main competitors and comparable companies include Cronos Group (MJN), Cara Operations (CARA), Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), and Hydropothecary (THCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Canopy Growth compare to Cronos Group?

Canopy Growth (TSE:WEED) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

In the previous week, Canopy Growth had 1 more articles in the media than Cronos Group. MarketBeat recorded 2 mentions for Canopy Growth and 1 mentions for Cronos Group. Canopy Growth's average media sentiment score of 0.78 beat Cronos Group's score of 0.67 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A
Cronos Group	N/A	N/A	N/A	N/A	N/A

4.1% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cronos Group	N/A	N/A	N/A

Canopy Growth presently has a consensus price target of C$1.88, suggesting a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Canopy Growth beats Cronos Group on 8 of the 11 factors compared between the two stocks.

How does Canopy Growth compare to Cara Operations?

Cara Operations (TSE:CARA) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

4.1% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Canopy Growth had 2 more articles in the media than Cara Operations. MarketBeat recorded 2 mentions for Canopy Growth and 0 mentions for Cara Operations. Canopy Growth's average media sentiment score of 0.78 beat Cara Operations' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Cara Operations	Neutral
Canopy Growth	Positive

Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cara Operations has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A

Cara Operations has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cara Operations' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Canopy Growth	-73.95%	-29.85%	-3.83%

Summary

Canopy Growth beats Cara Operations on 8 of the 11 factors compared between the two stocks.

How does Canopy Growth compare to Cronos Group?

Cronos Group (TSE:CRON) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

4.4% of Cronos Group shares are held by institutional investors. Comparatively, 4.1% of Canopy Growth shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cronos Group has a net margin of 38.95% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 6.46% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	38.95%	6.46%	-3.73%
Canopy Growth	-73.95%	-29.85%	-3.83%

Cronos Group presently has a consensus price target of C$4.92, suggesting a potential upside of 14.88%. Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 35.87%. Given Canopy Growth's higher possible upside, analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cronos Group has a beta of 1.13355, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.382001, suggesting that its stock price is 38% more volatile than the broader market.

Cronos Group has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$179.09M	8.80	-C$32.78M	C$0.19	22.53
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A

In the previous week, Cronos Group and Cronos Group both had 2 articles in the media. Canopy Growth's average media sentiment score of 0.78 beat Cronos Group's score of 0.47 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cronos Group beats Canopy Growth on 11 of the 15 factors compared between the two stocks.

How does Canopy Growth compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

DRI Healthcare Trust has a beta of 0.350693, meaning that its share price is 65% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.382001, meaning that its share price is 38% more volatile than the broader market.

DRI Healthcare Trust currently has a consensus price target of C$25.20, suggesting a potential upside of 38.77%. Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 35.87%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts clearly believe DRI Healthcare Trust is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

DRI Healthcare Trust has higher earnings, but lower revenue than Canopy Growth. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$172.34M	5.80	C$9.73M	-C$0.80	N/A
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A

DRI Healthcare Trust has a net margin of 5.02% compared to Canopy Growth's net margin of -73.95%. DRI Healthcare Trust's return on equity of 2.06% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Canopy Growth	-73.95%	-29.85%	-3.83%

0.8% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 4.1% of Canopy Growth shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by company insiders. Comparatively, 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, DRI Healthcare Trust had 3 more articles in the media than Canopy Growth. MarketBeat recorded 5 mentions for DRI Healthcare Trust and 2 mentions for Canopy Growth. DRI Healthcare Trust's average media sentiment score of 1.12 beat Canopy Growth's score of 0.78 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DRI Healthcare Trust	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DRI Healthcare Trust beats Canopy Growth on 11 of the 17 factors compared between the two stocks.

How does Canopy Growth compare to Hydropothecary?

Canopy Growth (TSE:WEED) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Hydropothecary has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A
Hydropothecary	N/A	N/A	N/A	N/A	N/A

Canopy Growth presently has a consensus target price of C$1.88, indicating a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher possible upside, research analysts plainly believe Canopy Growth is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.1% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hydropothecary has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Hydropothecary's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Hydropothecary	N/A	N/A	N/A

In the previous week, Canopy Growth had 2 more articles in the media than Hydropothecary. MarketBeat recorded 2 mentions for Canopy Growth and 0 mentions for Hydropothecary. Canopy Growth's average media sentiment score of 0.78 beat Hydropothecary's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Positive
Hydropothecary	Neutral

Summary

Canopy Growth beats Hydropothecary on 8 of the 11 factors compared between the two stocks.

Get Canopy Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WEED vs. The Competition

Export

Metric	Canopy Growth	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$582.57M	C$11.72B	C$6.98B	C$12.55B
Dividend Yield	4.80%	2.70%	2.58%	6.20%
P/E Ratio	-2.06	781.44	269.27	30.74
Price / Sales	1.98	748.15	597.31	9.76
Price / Cash	1.63	67.45	70.53	82.29
Price / Book	0.85	10.77	13.07	4.64
Net Income	-C$1.05B	C$2.78B	C$3.45B	C$299.09M
7 Day Performance	0.73%	-0.17%	0.74%	0.92%
1 Month Performance	2.99%	0.00%	1.40%	3.90%
1 Year Performance	-33.01%	161.17%	67.03%	36.15%

Canopy Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WEED Canopy Growth	2.4669 of 5 stars	C$1.38 -2.1%	C$1.88 +35.9%	-37.9%	C$582.57M	C$293.63M	N/A	2,700	Earnings Report
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
CRON Cronos Group	2.9829 of 5 stars	C$4.30 +2.6%	C$4.92 +14.3%	+21.8%	C$1.58B	C$179.09M	22.63	450
DHT.UN DRI Healthcare Trust	3.3647 of 5 stars	C$18.66 +3.6%	C$25.20 +35.0%	+21.9%	C$1.03B	C$163.77M	N/A	N/A	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:WEED) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canopy Growth (WEED) Competitors

WEED vs. MJN, CARA, CRON, DHT.UN, and THCX

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cara Operations?

Summary

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to DRI Healthcare Trust?

Summary

How does Canopy Growth compare to Hydropothecary?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Canopy Growth (WEED) Competitors

WEED vs. MJN, CARA, CRON, DHT.UN, and THCX

How does Canopy Growth compare to Cronos Group?

Does the media prefer WEED or MJN?

Which has better earnings and valuation, WEED or MJN?

Do insiders and institutionals hold more shares of WEED or MJN?

Is WEED or MJN more profitable?

Do analysts prefer WEED or MJN?

Summary

How does Canopy Growth compare to Cara Operations?

Do insiders & institutionals believe in CARA or WEED?

Does the media favor CARA or WEED?

Do analysts prefer CARA or WEED?

Which has higher earnings and valuation, CARA or WEED?

Is CARA or WEED more profitable?

Summary

How does Canopy Growth compare to Cronos Group?

Do institutionals and insiders hold more shares of CRON or WEED?

Is CRON or WEED more profitable?

Do analysts prefer CRON or WEED?

Which has more volatility & risk, CRON or WEED?

Which has preferable valuation & earnings, CRON or WEED?

Does the media favor CRON or WEED?

Summary

How does Canopy Growth compare to DRI Healthcare Trust?

Which has more volatility and risk, DHT.UN or WEED?

Do analysts rate DHT.UN or WEED?

Which has better valuation and earnings, DHT.UN or WEED?

Is DHT.UN or WEED more profitable?

Do insiders & institutionals hold more shares of DHT.UN or WEED?

Does the media favor DHT.UN or WEED?

Summary

How does Canopy Growth compare to Hydropothecary?

Which has better valuation and earnings, WEED or THCX?

Do analysts rate WEED or THCX?

Do insiders and institutionals have more ownership in WEED or THCX?

Is WEED or THCX more profitable?

Does the media prefer WEED or THCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools